Trigkidis Kyriakos, Geladari Eleni, Kokkinakis Evangelos, Vallianou Natalia
Evangelismos General Hospital, Athens, Greece.
Eur J Rheumatol. 2017 Jun;4(2):139-141. doi: 10.5152/eurjrheum.2017.16066. Epub 2017 Apr 11.
There is growing concern regarding the emergence of visceral leishmaniasis (VL), a disseminated parasitic disease caused by protozoa of the genus Leishmania, as an opportunistic infection in immunocompromised patients. This association has been principally studied in the context of human immunodeficiency virus infection, but VL has also been reported in patients undergoing treatment with immunosuppressive medication for various indications. Here a case of VL in a patient with rheumatoid arthritis undergoing treatment with methotrexate and corticosteroid is presented. Despite the rarity of such incidents, physicians should include VL in the differential diagnosis because this infection, if left untreated, is characterized by significant mortality.
内脏利什曼病(VL)是一种由利什曼原虫属原生动物引起的播散性寄生虫病,作为免疫功能低下患者的机会性感染,其出现越来越受到关注。这种关联主要是在人类免疫缺陷病毒感染的背景下进行研究的,但在因各种适应症接受免疫抑制药物治疗的患者中也有VL的报道。本文介绍了一例正在接受甲氨蝶呤和皮质类固醇治疗的类风湿性关节炎患者发生VL的病例。尽管此类事件罕见,但医生应将VL纳入鉴别诊断,因为这种感染若不治疗,死亡率很高。